INmune Bio, Inc. (Nasdaq: INMB) is a clinical-stage immunology company that is exclusively focused on modulating components of the Innate Immune system to treat diseases. The company has 5 clinical programs in phase 1 or phase 2 in 2020 between two unique product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for cancer (INB03), Alzheimer’s (XPro1595), and NASH (LivNate). The Innate Immune Priming Platform includes INKmune aimed at priming the patient’s NK cells to eliminate the minimal residual disease in patients with cancer. To learn more, please visit www.inmunebio.com.

Learn more at www.inmunebio.com

Presentation

Research Coverage

H.C. Wainwright & Co.

Recent Events

DON'T SEE YOUR CITY?

Request an event

BACK TO EVENTS